A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

Abstract
Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients with unstable angina or acute myocardial infarction.